Techcyte adds PathTools prostate analysis to Fusion AP

Techcyte said PathTools’ gland-level prostate analysis is now available on Fusion AP, giving pathologists quantitative measurements to support biopsy review. The integration is designed to help users assess Gleason patterns, tumor area, cribriform architecture and perineural invasion inside a single workflow.

Why it matters: - Prostate biopsy review depends on precise pattern counting and gland-level assessment, which can be difficult to estimate by eye. - The integration gives pathologists quantitative measurements they can inspect and verify alongside the slide and case. - The workflow is designed to support both subspecialists and general pathologists handling prostate cases.

What happened: - Techcyte announced that PathTools’ prostate analysis algorithms are now available on Techcyte Fusion AP. - The announcement was made Oct. 8, 2026, from Orem, Utah. - The integration brings gland-level prostate analysis into Techcyte’s enterprise digital pathology platform.

The details: - PathTools classifies each gland as benign or Gleason pattern 3, 4 or 5. - The software calculates counts and areas for each pattern. - Pathologists can inspect the annotations and accept or override individual gland classifications. - PathTools also reports the dominant pattern and the proportion of tissue area classified as tumor. - The software separately flags cribriform architecture and perineural invasion. - Techcyte said the tools are deeply integrated into the Fusion case view and slide viewer. - Pathologists can review gland-level annotations on the slide and see the associated counts and measurements in the same platform. - A product whitepaper is available here. - Techcyte will show PathTools on Fusion AP at Pathology Visions 2026 on Oct. 16-18 in San Diego at booth 410. - Techcyte also invited attendees to schedule a demo. - PathTools and Fusion AP are intended for research use in the United States. - Techcyte Fusion is for Research Use Only in the United States.

Between the lines: - The product pitch centers on moving prostate grading from subjective visual estimation toward measurable gland-by-gland review. - The integration keeps AI output close to the slide, which may reduce friction in adoption by fitting into existing review habits. - Techcyte is positioning Fusion AP as a platform for third-party AI tools, not just a standalone viewer.

What's next: - Techcyte plans to demonstrate the integration publicly at Pathology Visions 2026. - Laboratories and pathologists interested in the workflow can review the whitepaper or request a demo. - The company’s broader expansion appears tied to adding more AI tools to the Fusion ecosystem.